Published in Lancet Infect Dis on June 01, 2003
Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol (2010) 1.33
Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol (2014) 1.06
Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Endocrine (2011) 0.96
Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment. J Infect Dis (2009) 0.85
Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon. AIDS Res Ther (2014) 0.82
Short communication: Severe symptomatic hyperlactatemia among HIV type 1-infected adults on antiretroviral therapy in Côte d'Ivoire. AIDS Res Hum Retroviruses (2010) 0.80
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals. BMC Res Notes (2012) 0.79
A computational model of mitochondrial AZT metabolism. Biochem J (2005) 0.77
HIV-infected and Uninfected Adults with Non-Genotype 3 Hepatitis C Virus Have Less Hepatic Steatosis than Adults with Neither Infection. Hepatology (2016) 0.75
Is there a role for nitric oxide in hyperlactataemia syndromes and mitochondrial dysfunction associated with HIV therapy? Lancet Infect Dis (2003) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol (2003) 8.23
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Nonalcoholic fatty liver disease. Gastroenterology (2002) 4.15
Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology (2003) 4.03
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology (2014) 4.01
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology (2010) 3.73
Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA (2003) 3.51
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. Hepatology (2005) 3.35
Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol (2008) 3.33
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology (2012) 2.93
Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest (2008) 2.89
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol (2011) 2.56
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology (2013) 2.42
Hematopoietic stem cells convert into liver cells within days without fusion. Nat Cell Biol (2004) 2.41
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology (2010) 2.37
Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis (2008) 2.35
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am J Pathol (2003) 2.27
Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology (2009) 2.25
Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. Stem Cells (2008) 2.24
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology (2014) 2.23
Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol (2009) 2.23
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20
Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol (2007) 2.16
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol (2011) 2.15
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab Invest (2007) 2.03
The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice. Hepatology (2014) 2.03
Hedgehog signaling maintains resident hepatic progenitors throughout life. Am J Physiol Gastrointest Liver Physiol (2005) 2.02
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology (2003) 2.00
Epithelial-to-mesenchymal transitions in the liver. Hepatology (2009) 1.99
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis (2005) 1.91
Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89
Smoothened is a master regulator of adult liver repair. J Clin Invest (2013) 1.89
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. Gastroenterology (2008) 1.84
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology (2010) 1.82
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Hedgehog signaling in the liver. J Hepatol (2010) 1.80
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology (2009) 1.79
Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.75
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
Interleukin-15 increases hepatic regenerative activity. J Hepatol (2006) 1.72
Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology (2008) 1.71
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Signals from dying hepatocytes trigger growth of liver progenitors. Gut (2010) 1.67
Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production. Hepatology (2009) 1.65
Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65
Hepatic allograft-derived Kupffer cells regulate T cell response in rats. Liver Transpl (2003) 1.65
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62
Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol (2008) 1.62
Role for hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest (2005) 1.62
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol (2012) 1.61
Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology (2010) 1.57
Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology (2012) 1.57
The adventures of sonic hedgehog in development and repair. II. Sonic hedgehog and liver development, inflammation, and cancer. Am J Physiol Gastrointest Liver Physiol (2008) 1.56
Macrophage-derived Hedgehog ligands promotes fibrogenic and angiogenic responses in human schistosomiasis mansoni. Liver Int (2012) 1.55
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53